Hengqu (hetrombopag) / Jiangsu Hengrui Pharma - LARVOL DELTA

Romiplostim for cancer treatment-induced thrombocytopenia in acute promyelocytic leukemia: a case report. (PubMed, Front Oncol) - "All-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) is a first-line treatment regimen for acute promyelocytic leukemia (APL), with generally milder myelosuppressive effects compared with conventional chemotherapy...A 60-year-old female patient with APL developed refractory grade 3-4 thrombocytopenia during ATO maintenance therapy, with no significant response to recombinant human thrombopoietin or hetrombopag treatment (platelet nadir: 8 × 109/L; duration of platelet count <50 × 109/L: 8 weeks)...Romiplostim may promote the recovery of residual megakaryopoietic capacity and provide a potential therapeutic option for such patients. However, its precise mechanism of action and the patient populations most likely to benefit require further investigation."

Journal • Acute Promyelocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Thrombocytopenia

Efficacy and safety of different TPO-RAs combined with cyclosporine in the treatment of NSAA. (PubMed, Ther Adv Hematol) - "Currently, three small-molecule TPO-RAs (eltrombopag, hetrombopag, and avatrombopag) are available for clinical use and work well...A retrospective analysis was performed to assess the efficacy and side effects of cyclosporine A (CsA) combined with different TPO - RAs in 67 NSAA patients...Similar to SAA, NSAA patients should also be initiated with an adequate dose of TPO-RAs therapy. Elderly patients and those with concurrent infections are at higher risk of mortality, prolonged hospitalizations, and require more clinical attention."

Journal • Aplastic Anemia • Hematological Disorders • Hepatology • Infectious Disease • Liver Failure

Study on the combination of Herombopag and recombinant human thrombopoietin in the treatment of sepsis-associated thrombocytopenia (ChiCTR) - P=N/A | N=120 | Not yet recruiting | Sponsor: The Affiliated Hospital of Xuzhou Medical University; The Affiliated Hospital of Xuzhou Medical University

New trial • Hematological Disorders • Infectious Disease • Septic Shock • Thrombocytopenia

Clinical study on the efficacy and safety of eltrombopag olamine tablets in secondary prevention of chemotherapy-induced thrombocytopenia in rare tumors (ChiCTR) - P2 | N=44 | Not yet recruiting | Sponsor: The Afliated Cancer Hospital of Shandong First Medical University; The Afliated Cancer Hospital of Shandong First Medical University

New P2 trial • Hematological Disorders • Oncology • Thrombocytopenia

A Multicenter, Randomized, Controlled Clinical Study of Hetrombopag Olamine versus Recombinant Human Thrombopoietin in the Treatment of Cancer Therapy Induced Thrombocytopenia (ChiCTR) - P=N/A | N=366 | Recruiting | Sponsor: Henan Cancer Hospital; Henan Cancer Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Thrombocytopenia

Jiangsu Hengrui Pharmaceuticals has received approval from China’s National Medical Products Administration for two new indications of its self-developed Class 1 innovative drug, Hetrombopag Olamine Tablets. (TipRanks) - "The approvals cover use in adult patients suffering thrombocytopenia caused by chemotherapy-based anti-tumor therapy for solid tumors and in pediatric patients aged six and above with chronic primary immune thrombocytopenia who respond poorly to standard treatments..."

China approval • Immune Thrombocytopenic Purpura • Thrombocytopenia

Cost-effectiveness analysis of eltrombopag, hetrombopag and romiplostim for second-line treatment of primary immune thrombocytopenia in China. (PubMed, Front Med (Lausanne)) - "Eltrombopag was likely to be the most cost-effective second-line treatment option for ITP compared with hetrombopag and romiplostim. Our findings provide economic evidence to support decision-making regarding the use of TPO-RAs in China."

HEOR • Journal • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

Hetrombopag for the treatment of lower-risk myelodysplastic syndromes with thrombocytopenia: A prospective, single-arm, multicenter study (ASH 2025) - P=N/A | "Hetrombopag is effective in increasing platelet counts and demonstrates an acceptabletoxicity profile in LR-MDS patients with thrombocytopenia, suggesting that hetrombopag may be apromising new therapeutic option for this population. Nevertheless, further larger, prospective andcontrolled studies are warranted to better define the role of hetrombopag in the treatment of LR-MDS."

Clinical • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Hematological Disorders • Hematological Malignancies • Immune Thrombocytopenic Purpura • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Thrombocytopenia • Thrombocytopenic Purpura • ASXL1 • BCOR • DNMT3A • U2AF1

A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient (clinicaltrials.gov) - P1/2 | N=55 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Phase classification: P2 ➔ P1/2

Phase classification • Anemia • Aplastic Anemia • Hematological Disorders

Efficacy and safety comparison of hetrombopag and eltrombopag in children with cancer therapy-induced thrombocytopenia: a single-center retrospective study. (PubMed, Front Med (Lausanne)) - "In pediatric CTIT patients, eltrombopag was linked to improved platelet response and less transfusion dependence, accompanied by a tolerable safety profile. As the first study focusing on eltrombopag for pediatric CTIT, these findings provide critical evidence supporting its clinical application as a promising therapeutic option for this understudied population."

Journal • Retrospective data • Hematological Disorders • Leukopenia • Oncology • Pediatrics • Thrombocytopenia • Thrombocytosis

The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery (clinicaltrials.gov) - P3 | N=127 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Aug 2026 | Trial primary completion date: Dec 2026 ➔ Aug 2026

Trial completion • Trial completion date • Trial primary completion date • Hematological Disorders • Hepatology • Thrombocytopenia

First-line hetrombopag combined with immunosuppressive therapy for paediatric severe aplastic anaemia: A prospective randomized controlled trial. (PubMed, Br J Haematol) - "Adding HPAG to first-line IST did not significantly improve early or sustained haematological response rates in paediatric SAA. Routine upfront combination therapy is not warranted for most patients."

Journal • Anemia • Aplastic Anemia • Hematological Disorders • Pediatrics

Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia (clinicaltrials.gov) - P4 | N=38 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China

New P4 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Hetrombopag for enhancement of platelet engraftment after allogeneic hematopoietic stem cell transplantation: A single-center experience. (PubMed, Ther Adv Hematol) - "Hetrombopag significantly accelerates platelet engraftment and has a favorable safety profile, suggesting its potential as a therapeutic adjunct in managing thrombocytopenia post-allo-HSCT. This study complements and validates findings from prior prospective studies, providing external confirmation in a real-world cohort."

Journal • Bone Marrow Transplantation • Hematological Disorders • Thrombocytopenia • Transplantation

Analysis of Predictive Factors for Discontinuation of Hetrombopag in Patients with Chronic Primary Immune Thrombocytopenia (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi) - "Duration of drug withdrawal is a protective factor for achieving SROT in CITP patients receiving hetrombopag, while the ratio of CD19+ to CD45+ cells is a risk factor. Combined detection of drug withdrawal duration and pre-treatment ratio of CD19+ to CD45+ cells has high predictive value for identifying whether CITP patients can achieve SROT after hetrombopag treatment."

Biomarker • Journal • Retrospective data • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura • CD8 • PTPRC

Network meta-analysis comparing the efficacy of subsequent treatment regimens in primary immune thrombocytopenia patients (ISTH 2026) - "In placebo- controlled studies, Romiplostim showed the highest efficacy, followed by Hetrombopag, Eltrombopag, Fostamatinib, and Rilzabrutinib. In studies using Danazol as the control, ATRA plus danazol had the highest efficacy, followed by Tacrolimus plus danazol and rhTPO plus danazol. In studies using Eltrombopag as the control, the Eltrombopag plus diacerein regimen was more effective than rhTPO. Conclusions These results furnish high-quality evidence to support evidence-based, individualized selection of subsequent therapy for adults with relapsed/refractory primary immune thrombocytopenia. Table or Figure Upload (1) Figure 1.Network meta-analysis comparing the efficacy of subsequent treatment regimens Page 2 DOI*10.1016/j.rpth.2026.104395"

Retrospective data • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT (clinicaltrials.gov) - P=N/A | N=30 | Completed | Sponsor: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine | Enrolling by invitation ➔ Completed

Trial completion • Bone Marrow Transplantation • Genetic Disorders • Transplantation

TPO-RA Plus Baricitinib vs. TPO-RA for ITP (clinicaltrials.gov) - P2 | N=100 | Not yet recruiting | Sponsor: Peking University People's Hospital

New P2 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Advances and Clinical Applications of Thrombopoietic Agents. (PubMed, Curr Med Sci) - "This review evaluates the mechanisms and clinical utility of contemporary therapies, spanning from recombinant human thrombopoietin (rhTPO) and established TPO-RAs (eltrombopag, romiplostim, and herombopag) to emerging classes such as spleen tyrosine kinase (SYK) and Bruton tyrosine kinase (BTK) inhibitors. Despite these advancements, challenges including inconsistent response rates, long-term safety considerations, and accessibility barriers persist. Looking ahead, the field is pivoting toward personalized management strategies and next-generation agents to further refine patient care and optimize clinical outcomes."

Journal • Review • Aplastic Anemia • Hematological Disorders • Hepatology • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura • SYK

Efficacy and safety of hetrombopag in children with primary immune thrombocytopenia: a longitudinal prospective cohort study (ISTH 2026) - P | "Conclusions These findings suggest that hetrombopag has efficacy, durability and a favorable safety profile in pediatric patients, even in those with prior eltrombopag unresponsive or relapse. DOI*10.1016/j.rpth.2026.104435"

Clinical • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Preliminary experience with oral thrombopoietin-receptor agonists, primarily hetrombopag, in pediatric immune thrombocytopenia: a pilot single-center retrospective report. (PubMed, Transl Pediatr) - "We conducted a single-center retrospective study of 18 children with ITP treated with oral TPO-RAs (hetrombopag, eltrombopag, or avatrombopag) at Qingdao Women and Children's Hospital from January 2023 to June 2024. In this preliminary, pilot-scale hetrombopag-predominant cohort, oral TPO-RA use was associated with increased platelet counts; however, the limited sample size and lack of statistically significant improvement in bleeding scores preclude definitive conclusions regarding the overall clinical utility of these agents beyond their ability to increase platelet counts. Given the retrospective design, heterogeneity of exposure, and limited sample size, the findings are hypothesis-generating and should be confirmed in prospective studies."

Journal • Retrospective data • Hematological Disorders • Immune Thrombocytopenic Purpura • Infectious Disease • Pediatrics • Thrombocytopenia • Thrombocytopenic Purpura

A Retrospective Analysis of Low-Dose Decitabine combined with thrombopoietin receptor agonists for Refractory Severe Cancer therapy-induced thrombocytopenia: Efficacy, Safety, and Prognostic Factors (ISTH 2026) - "Methods This study retrospectively collected 96 CTIT patients receiving low-dose Decitabine (3.5 mg/m²/day for 3 consecutive days) combined with TPO-RAs (including eltrombopag, hetrombopag, avatrombopag, romiplostim, or rhTPO) from January 2019 to April 2025. Baseline Characteristics of the Enrolled Patients Page 2 Page 3 Table or Figure Upload (2) Table 2. Summary of Treatment Efficacy for the Combination Regimen DOI*10.1016/j.rpth.2026.106073"

Biomarker • Retrospective data • Leukopenia • Neutropenia • Oncology • Thrombocytopenia • Venous Thromboembolism

The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery (clinicaltrials.gov) - P3 | N=127 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • Hematological Disorders • Hepatology • Thrombocytopenia

Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support. (PubMed, Front Oncol) - "The thrombocytopenia was refractory to recombinant human thrombopoietin and hetrombopag. As adjuvant antibody-drug conjugate (ADC) strategies continue to evolve, this case suggests that severe non-cyclic thrombocytopenia may occur early during HER2-directed ADC therapy. It supports the value of sequential marrow assessment in selected refractory cases and provides clinical context for individualized romiplostim support in prolonged thrombocytopenia."

Journal • Breast Cancer • Fibrosis • Hematological Disorders • HER2 Breast Cancer • HER2 Positive Breast Cancer • Immunology • Oncology • Solid Tumor • Thrombocytopenia

Safety and Effectiveness of Trappa Ethanolamine Tablets Combined With Ciclosporin in the Treatment of Primary Treatment of Non-severe Aplastic Anemia (clinicaltrials.gov) - P2 | N=108 | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | N=78 ➔ 108

Enrollment change • Anemia • Aplastic Anemia • Hematological Disorders